PRVA
NEUTRAL
$24.02
Live
Privia Health Group, Inc. · NASDAQ
Target $31.8
(+32.4%)
$18.77
52W Range
$26.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 18, 2026
Market cap
$3.02B
P/E
126.42
ROE
4.0%
Profit margin
1.1%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
PRVA presents a stark contrast between fundamental value and growth expectations, anchored by a stable Piotroski F-Score of 4/9. While the company maintains an exceptionally clean balance sheet with near-zero debt, it trades at a massive premium compared to its Graham Number ($5.05) and Intrinsic Value ($5.61). Strong analyst conviction and impressive YoY earnings growth are currently offset by aggressive insider selling from the CEO and CFO and razor-thin profit margins. The stock is essentially a high-growth bet where the market is pricing in future earnings far beyond current deterministic valuations.
Key Strengths
Exceptionally low Debt/Equity ratio (0.01), indicating minimal financial leverage risk
Strong revenue growth (17.40% YoY) and explosive annual earnings growth (132.80%)
Consistent track record of beating earnings estimates (3 of last 4 quarters)
Strong analyst consensus with a 'strong_buy' rating and target price of $31.80
Healthy liquidity position with a Current Ratio of 1.60
Key Risks
Extreme valuation gap: Current price ($24.02) is >4x the Graham Number ($5.05)
Very thin profitability margins (Profit Margin: 1.08%, Gross Margin: 9.87%)
Bearish insider sentiment with significant selling by the CEO and CFO
Recent sharp decline in Q/Q EPS growth (-75.9%)
High trailing P/E ratio (126.42) makes the stock sensitive to any earnings miss
AI Fair Value Estimate
Based on comprehensive analysis
$8.45
-64.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
20
75
65
70
0
AI Verdict
Speculative Growth
Key drivers: Low Debt, High Growth Expectations, Valuation Premium, Insider Selling
Confidence
90%
Value
20/100
Ref P/E 126.42, Graham Number $5.05
Positives
- Forward P/E (20.08) is reasonable for the sector
Watchpoints
- Trailing P/E is excessive
- Price is significantly above Graham and Intrinsic values
Future
75/100
Ref 132.8% Earnings Growth
Positives
- Strong YoY Revenue and Earnings growth
- High analyst target price ($31.80)
Watchpoints
- Recent Q/Q EPS growth contraction
Past
65/100
Ref Quarterly Earnings Track Record
Positives
- Consistent history of earnings surprises
- Positive 1-year price change
Watchpoints
- Negative 3-year price performance
Health
70/100
Ref Piotroski F-Score 4/9, Debt/Equity 0.01
Positives
- Near-zero debt
- Stable Piotroski score
- Good current/quick ratios
Watchpoints
- Piotroski score is not in the 'Strong' range (4/9)
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$24.02
Analyst Target
$31.8
Upside/Downside
+32.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PRVA and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PRVA
Privia Health Group, Inc.
Primary
|
+4.4% | -7.2% | +1.4% | -5.9% | +11.3% | +7.4% |
|
BKD
Brookdale Senior Living Inc.
Peer
|
+153.4% | +367.5% | +163.2% | +72.4% | +18.9% | +6.2% |
|
ICUI
ICU Medical, Inc.
Peer
|
-38.8% | -28.3% | -9.2% | +10.1% | -6.0% | +1.9% |
|
BEAM
Beam Therapeutics Inc.
Peer
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
PRV
Privia Health Group, Inc.
Primary
5Y
+4.4%
3Y
-7.2%
1Y
+1.4%
6M
-5.9%
1M
+11.3%
1W
+7.4%
BKD
Brookdale Senior Living Inc.
Peer
5Y
+153.4%
3Y
+367.5%
1Y
+163.2%
6M
+72.4%
1M
+18.9%
1W
+6.2%
ICU
ICU Medical, Inc.
Peer
5Y
-38.8%
3Y
-28.3%
1Y
-9.2%
6M
+10.1%
1M
-6.0%
1W
+1.9%
BEA
Beam Therapeutics Inc.
Peer
5Y
-69.2%
3Y
-29.2%
1Y
+20.1%
6M
+45.3%
1M
+12.2%
1W
+1.1%
ARQ
Arcutis Biotherapeutics, Inc.
Peer
5Y
-30.1%
3Y
+98.3%
1Y
+53.6%
6M
+31.6%
1M
-14.4%
1W
-5.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
126.42
Forward P/E
20.08
PEG Ratio
N/A
P/B Ratio
4.03
P/S Ratio
1.42
EV/Revenue
1.2
EV/EBITDA
57.87
Market Cap
$3.02B
Profitability
Profit margins and return metrics
Profit Margin
1.08%
Operating Margin
2.08%
Gross Margin
9.87%
ROE
4.03%
ROA
1.71%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.4%
Earnings Growth
+132.8%
Q/Q Revenue Growth
+17.42%
Q/Q Earnings Growth
+108.0%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
1.6
Good
Quick Ratio
1.55
Excellent
Cash/Share
$3.88
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
9.2%
Op. Margin
2.1%
Net Margin
1.7%
Total Assets
$1.4B
Liabilities
$0.6B
Equity
$0.7B
Debt/Equity
0.78x
Operating CF
$0.1B
Free Cash Flow
$0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$0.07
+139.6% surprise
2025-11-06
$0.29
+33.7% surprise
2025-08-07
$0.24
+20.4% surprise
Healthcare Sector Comparison
Comparing PRVA against 418 companies in the Healthcare sector
(24 bullish, 134 neutral, 260 bearish)
P/E Ratio
126.42
This Stock
vs
89.67
Sector Avg
+41.0%
(Expensive)
Return on Equity (ROE)
4.03%
This Stock
vs
-101.05%
Sector Avg
-104.0%
(Below Avg)
Profit Margin
1.08%
This Stock
vs
-13.75%
Sector Avg
-107.9%
(Weaker)
Debt to Equity
0.01
This Stock
vs
3.24
Sector Avg
-99.6%
(Less Debt)
Revenue Growth
17.4%
This Stock
vs
121.5%
Sector Avg
-85.7%
(Slower)
Current Ratio
1.6
This Stock
vs
4.55
Sector Avg
-64.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PRVA
Privia Health Group, Inc.
|
NEUTRAL | $3.02B | 126.42 | 4.0% | 1.1% | $24.02 | |
|
BKD
Brookdale Senior Living Inc.
|
BEARISH | $3.08B | - | -212.3% | -9.9% | $12.95 | Compare |
|
ICUI
ICU Medical, Inc.
|
BEARISH | $3.14B | 4189.33 | 0.0% | 0.0% | $125.68 | Compare |
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | Compare |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | Compare |
PRVA
Privia Health Group, Inc.
NEUTRAL
Mkt Cap
$3.0B
P/E
126.4
ROE
4.0%
Price
$24.02
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | MOUNTCASTLE DAVID | Chief Financial Officer | Sale | 5,566 | $116,051 |
| 2026-03-16 | MOUNTCASTLE DAVID | Chief Financial Officer | Sale | 6,391 | $141,305 |
| 2026-03-16 | MEHROTRA PARTH | Chief Executive Officer | Sale | 26,509 | $586,114 |
| 2026-03-13 | MOUNTCASTLE DAVID | Chief Financial Officer | Sale | 13,018 | $282,600 |
| 2026-03-13 | MEHROTRA PARTH | Chief Executive Officer | Sale | 53,992 | $1,172,078 |
| 2026-03-11 | MOUNTCASTLE DAVID | Chief Financial Officer | Stock Award | 77,919 | - |
| 2026-03-11 | MEHROTRA PARTH | Chief Executive Officer | Stock Award | 313,246 | - |
| 2026-03-10 | MEHROTRA PARTH | Chief Executive Officer | Sale | 21,097 | $479,113 |
| 2026-03-10 | FARGIS EDWARD C. | General Counsel | Stock Award | 28,268 | - |
| 2026-03-09 | MOUNTCASTLE DAVID | Chief Financial Officer | Sale | 11,006 | $252,982 |
| 2026-03-09 | MEHROTRA PARTH | Chief Executive Officer | Sale | 63,439 | $1,456,239 |
| 2026-03-09 | FARGIS EDWARD C. | General Counsel | Sale | 9,343 | $214,756 |
| 2026-02-27 | MOUNTCASTLE DAVID | Chief Financial Officer | Sale | 13,058 | $326,835 |
| 2026-02-27 | MOUNTCASTLE DAVID | Chief Financial Officer | Option Exercise | 13,058 | $26,116 |
| 2026-02-27 | MORRIS MATTHEW SHAWN | Director | Sale | 24,338 | $608,372 |
MOUNTCASTLE DAVID
Chief Financial Officer
2026-04-02
5,566 shares
·
$116,051
MOUNTCASTLE DAVID
Chief Financial Officer
2026-03-16
6,391 shares
·
$141,305
MEHROTRA PARTH
Chief Executive Officer
2026-03-16
26,509 shares
·
$586,114
MOUNTCASTLE DAVID
Chief Financial Officer
2026-03-13
13,018 shares
·
$282,600
MEHROTRA PARTH
Chief Executive Officer
2026-03-13
53,992 shares
·
$1,172,078
MOUNTCASTLE DAVID
Chief Financial Officer
2026-03-11
77,919 shares
MEHROTRA PARTH
Chief Executive Officer
2026-03-11
313,246 shares
MEHROTRA PARTH
Chief Executive Officer
2026-03-10
21,097 shares
·
$479,113
FARGIS EDWARD C.
General Counsel
2026-03-10
28,268 shares
MOUNTCASTLE DAVID
Chief Financial Officer
2026-03-09
11,006 shares
·
$252,982
MEHROTRA PARTH
Chief Executive Officer
2026-03-09
63,439 shares
·
$1,456,239
FARGIS EDWARD C.
General Counsel
2026-03-09
9,343 shares
·
$214,756
MOUNTCASTLE DAVID
Chief Financial Officer
2026-02-27
13,058 shares
·
$326,835
MOUNTCASTLE DAVID
Chief Financial Officer
2026-02-27
13,058 shares
·
$26,116
MORRIS MATTHEW SHAWN
Director
2026-02-27
24,338 shares
·
$608,372
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
8-K
10-Q
8-K
8-K
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
20 analysts
Evercore ISI Group
2026-04-08
Outperform
Outperform
Barclays
2026-03-25
Equal-Weight
Equal-Weight
Citigroup
2026-03-03
Buy
Buy
Truist Securities
2026-03-02
Buy
Buy
Canaccord Genuity
2026-02-27
Buy
Buy
Stephens & Co.
2025-12-04
Overweight
Overweight
JP Morgan
2025-11-13
Overweight
Overweight
BMO Capital
2025-11-13
Outperform
Canaccord Genuity
2025-11-12
Buy
Buy
Barclays
2025-11-10
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning PRVA from our newsroom.
Newest → oldest
No matching news yet.